BerandaATHA • NASDAQ
add
Athira Pharma Inc
$0,47
Setelah Jam Perdagangan Normal:(1,06%)+0,0050
$0,48
Tutup: 18 Okt, 20.00.00 GMT-4 · USD · NASDAQ · Pernyataan Penyangkalan
Tutup sebelumnya
$0,45
Rentang hari
$0,44 - $0,49
Rentang tahun
$0,41 - $4,30
Kapitalisasi pasar
18,07Â jt USD
Volume Rata-Rata
701,55Â rb
Rasio P/E
-
Hasil dividen
-
Bursa utama
NASDAQ
Dalam berita
Keuangan
Laporan Pendapatan
Pendapatan
Laba bersih
| (USD) | Jun 2024info | Perubahan Y/Y |
|---|---|---|
Pendapatan | — | — |
Biaya operasional | 28,03Â jt | -11,42% |
Laba bersih | -26,86Â jt | 9,25% |
Margin laba bersih | — | — |
Penghasilan per saham | — | — |
EBITDA | -27,79Â jt | 11,50% |
Tarif pajak efektif | — | — |
Neraca
Total aset
Total liabilitas
| (USD) | Jun 2024info | Perubahan Y/Y |
|---|---|---|
Investasi tunai jangka pdk | 91,77Â jt | -50,69% |
Total aset | 111,25Â jt | -46,53% |
Total liabilitas | 27,92Â jt | 21,02% |
Total ekuitas | 83,34 jt | — |
Saham yang beredar | 38,44 jt | — |
Harga terhadap nilai buku | 0,21 | — |
Tingkat pengembalian aset | -57,27% | — |
Tingkat pengembalian modal | -72,62% | — |
Arus Kas
Perubahan kas bersih
| (USD) | Jun 2024info | Perubahan Y/Y |
|---|---|---|
Laba bersih | -26,86Â jt | 9,25% |
Kas dari operasi | -22,33Â jt | 8,04% |
Kas dari investasi | 26,56Â jt | -18,24% |
Kas dari pembiayaan | 148,00Â rb | -38,84% |
Perubahan kas bersih | 4,38Â jt | -48,14% |
Arus kas bebas | -21,19Â jt | -50,61% |
Tentang
Athira Pharma is a late clinical stage American biopharmaceutical company developing small molecules to restore neuronal health and stop the neurodegeneration brought on by diseases such as Alzheimer's disease and Parkinson's disease. The company's lead candidate, ATH-1017, is in human studies for Alzheimer's disease as of 2021.
The company was founded in 2011 and is headquartered in Seattle. Funding that supports the company is from both public and private investment groups including the Alzheimer's Drug Discovery Foundation, Dolby Family Ventures, the State of Washington's Life Sciences Discovery Fund, The W Fund, WRF Capital, and other private investors.
Leen Kawas served as the company's first President and CEO, but resigned in October 2021, after an independent special committee found she "altered images in scientific papers she authored." On October 21, 2021, Mark Litton, Ph.D., M.B.A. became chief executive officer. Wikipedia
Didirikan
2011
Kantor pusat
Situs
Karyawan
66
